Mannkind reported $193.48M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adma Biologics ADMA:US $ 222.77M 17.03M
Chemocentryx CCXI:US $ 345.17M 6.46M
Dynavax Technologies DVAX:US $ 955.4M 14.89M
Eli Lilly And LLY:US $ 17115.2M 150.5M
Halozyme Therapeutics HALO:US $ 541.94M 446.75M
Immunogen IMGN:US $ 373.87M 82.84M
Insmed INSM:US $ 674.73M 81.41M
JAZZ PHA JAZZ:US $ 2590.83M 89.98M
Karyopharm Therapeutics KPTI:US $ 242.45M 34.09M
Macrogenics MGNX:US $ 167.63M 50.57M
Mannkind MNKD:US $ 193.48M 9.21M
Minerva Neurosciences NERV:US $ 50.04M 5.66M
Novavax NVAX:US $ 2136M 211.4M
Novo Nordisk A Fs NVO:US $ 102979M 16442M
Peregrine Pharmaceuticals PPHM:US $ 180.64M 0.61M
Xencor XNCR:US $ 585.94M 79.97M